Therapeutics that target CPT-1A, originally developed to treat heart disease and diabetes, could be repurposed in the context of breast cancer as a way to achieve sustainable tumour control and as an adjunctive treatment to immunotherapies. This evidence concerns the gene CPT1A and heart disorder.